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Background 
Sodium cromoglycate was first introduced as an 
inhaled treatment for bronchial asthma in the late 
1960s. Initially, it was presented as 20 mg of sodium 
cromoglycate (SCG) combined with 0.1 mg of iso- 
prenaline sulphate in a capsule which was inhaled 
using a Spinhaler. Sodium cromoglycate without 
isoprenaline sulphate was introduced shortly after- 
wards and, subsequently, further formulations have 
been introduced. These include a 1% aqueous sol- 
ution containing 20 mg SCG for nebulization, a 
metered dose inhaler (MDI) delivering 1 mg SCG 
per actuation, an MD1 delivering 5 mg SCG per 
actuation and an MD1 delivering 1 mg of SCG and 
0.1 mg of salbutamol per actuation. The most com- 
monly used form at present is the MD1 delivering 
5 mg per actuation. 
Absolute Efficacy 
The data supporting the position of inhaled SCG 
as an anti-inflammatory treatment for bronchial 
asthma has been reviewed recently (1). 
The absolute efficacy of inhaled SCG was estab- 
lished in both adult and paediatric asthma in a series 
of clinical trials carried out both in the U.K. and 
in other countries (2-10). The two definitive trials 
carried out in the U.K. (4,5) used the percentage of 
asthmatic patients who could be maintained satisfac- 
torily on treatment with SCG over a period of 1 yr as 
an end-point. In the trial carried out in adult patients 
(4) this was 74% and, in the paediatric trial (S), was 
71%. Both these studies were carried out using 20 mg 
Spincaps four times daily. 
Although many trials have been undertaken since 
then, they have not altered the conclusions of the 
original trials; that inhaled SCG is an effective 
treatment in 70% of asthmatic patients. 
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The remainder of this paper will concentrate on 
recent trials with the 5 mg MD1 as this is the most 
widely used form. 
Deposition in the Lung 
Currently available techniques of labelling drugs 
with Technitium 99 allow investigation in viva of the 
amount of an inhaled drug reaching the lung and its 
distribution within the lung. A study with inhaled 
SCG delivered as a dry powder from the Spinhaler 
(11) shows that the percentage of the dose delivered 
to the lung varies from a mean of 5.5% (range 
169.7%) at an inhalation rate of 60 1 min - ’ to 
17.1% (range 7.8283%) at an inhalation rate of 
120 lmin- ‘. In milligram terms, this means that 
between 1.1 mg and 3.42 mg of the 20 mg nominal 
dose is delivered to the lung. Using similar tech- 
niques, the same group (12) have shown that with 
the 5 mg aerosol, the amount of inhaled SCG 
reaching the lung is 88% (SEM 1.1) with a standard 
MDI, and 11.3% (SEM 1.9) using an MD1 with a small 
volume spacer at a slow (28.9 1 min - ‘) inhalation. 
Expressing these results as milligrams, from a 
standard unit dose of two actuations of the MDI, 
0.88 mg is delivered to the lung with an MD1 alone 
and 1.13 mg when the MD1 is used together with a 
spacer. 
In a study of male infants aged between 9 and 36 
months (13) which compared the concentration of 
SCG in the urine following administration either by 
face mask and nebulizer or by face mask, spacer and 
MD1 concluded that about 0.3% (0.06 mg of 20 mg 
dose) was deposited in the lung with the MD1 and 
spacer, and 1.5% (0.3 mg) from the nebulizer. In a 
study of premature infants (gestational age 2541 
weeks) who were being ventilated with intermittent 
positive pressure ventilation (14) it was estimated 
that 1.3% (0.26 mg) of a 20mg dose delivered by 
an ultrasonic nebulizer into the ventilator circuit 
reached the lung, and 1.7% (0.26 mg) of a 15 mg dose 
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administered as three actuations of a 5 mg MD1 
through a spacer and face mask. 
Studies with MD1 Delivering 5 mg per Actuation 
CHALLENGE STUDIES 
The dose-response relationships of the aerosol 
forms of inhaled SCG have been demonstrated in a 
series of trials involving exercise challenge (15-17) 
fog (18) and cold, dry air (19). These demonstrate 
that increased doses using the 5 mg MD1 provide 
better protection against challenge, a longer duration 
of protection and protects more subjects. 
The 5 mg MD1 has been shown to provide good 
protection against exercise challenge in both adults 
(20) and children (21,22). The degree of protection 
has been shown to improve on regular treatment (23). 
Evidence of significant protection against antigen 
challenge attenuating both the early and late 
asthmatic response are provided in a series of studies 
by Cockcroft et al. (24-26). These studies compare 
the effects of SCG, beclomethasone dipropionate, 
salbutamol, ketotifen, clemastine and theophylline 
in antigen challenge and subsequent increases in 
bronchial reactivity. They show that only SCG and 
beclomethasone dipropionate attenuate the late 
asthmatic reaction to antigen challenge and prevent 
the increase in reactivity. 
Other challenge studies demonstrate that inhaled 
SCG delivered as two actuations of the 5 mg MD1 
provide useful protection against cough induced by 
angiotensin-converting-enzyme drugs and capsaicin 
(27) and bronchoconstriction induced by adenosine 
monophosphate (28), substance P (29), bradykinin 
(30) and sodium metabisulphite (31). 
THERAPEUTIC STUDIES 
The absolute efficacy of the 5 mg MD1 formulation 
of SCG has been established in placebo-controlled 
trials in adults (32-34) and children (35). The key 
features from these studies are as follows. In the 
study by Carrasco and Sepulveda (32), there was a 
mean increase of 15% in peak expiratory flow rate 
(PEFR) measured in the morning in all patients 
(placebo 4%: WO.05) but a 30% increase in the most 
severe patients (those with a diurnal variation in 
PEFR greater than 15%: BO.01). In the study 
carried out in the U.S.A. (33), there was a 35% 
reduction in the severity of day and night asthma 
(placebo 7%, P=O.O12) and significant improvements 
in all measures of lung function (PcO.03). The study 
by Acheson et al. was a multi-centre study carried out 
in general practice in the U.K. and demonstrated 
‘good efficacy particularly as reflected by morning 
peak flow readings’, in the group treated with 10 mg 
(two actuations) of inhaled SCG administered twice 
daily. In the paediatric study (35), the mean age of 
the children was 3.7 years (range 2-6 years) and the 
drug was delivered using a large volume spacer. The 
dose used was 10 mg four times daily. There was a 
significant reduction in daytime and night-time cough 
and a significant reduction in asthma severity com- 
pared to placebo after 2 weeks of treatment (WO.05). 
Other studies have demonstrated that 10 mg four 
times daily of inhaled SCG is clinically equivalent to 
1OOpg four times daily of beclomethasone dipro- 
pionate (36) and also to 4 mg four times daily of 
nedocromil sodium (37), and can produce equivalent 
reductions in bronchial reactivity over 12 weeks to 
both beclomethasone dipropionate and nedocromil 
sodium (38). All of these studies were carried out in 
adult patients. In three paediatric studies, 10 mg of 
SCG given four times daily was shown to be superior 
to both placebo and oral ketotifen (39), and 10 mg 
given three times daily through a large volume spacer 
(40) could substitute over a 6-week period for 200 pg 
of inhaled beclomethasone dipropionate without loss 
of asthma control. In the final study (41), inhaled 
SCG at a dose of 10 mg four times daily delivered 
via a spacer could reduce the severity of both upper 
and lower respiratory symptoms in infants aged 
4-31 months who had been born prematurely. 
LONG-TERM EFFECTS 
The beneficial long-term effects of inhaled SCG 
were established in early trials (42,43). In the study by 
Godfrey et al. (43) which followed the children in the 
original placebo-controlled study for 3-5 years, 65% 
of 46 children remained well-controlled as measured 
by the lack of need to change to corticosteroid 
treatment. In a lo-yr follow-up study (44) of 50 
children with chronic perennial asthma, Dickson and 
Cole showed a consistent improvement in lung func- 
tion and a reduced dosage requirement for Intal. In 
the most recent study (45), Koenig reviewed 175 
children who have been followed for 2.2-16.8 yr 
(mean 8.4 yr). Pulmonary function improved to 
normal values in both groups treated with SCG and 
corticosteroids. 
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